Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro

European Journal of Clinical Pharmacology

Volumn 60, Issue 8, 2004, Pages 565-568

  Tanaka, Einosuke ^a   Takano, Yui ^a   Inomata, Shinichi ^a   Toyooka, Hidenori ^a   Honda, Katsuya ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Drug interaction; Microsomes; Propofol

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; CIMETIDINE; CLONIDINE; DIAZEPAM; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPNOTIC AGENT; LIDOCAINE; LOCAL ANESTHETIC AGENT; MIDAZOLAM; NEUROMUSCULAR DEPOLARIZING AGENT; PROPOFOL; PSYCHOTROPIC AGENT; THIAMYLAL; THYMOL; VECURONIUM;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; EXAMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS CONSTANT; PREMEDICATION; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; VELOCITY;

ANESTHETICS, INTRAVENOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; PREANESTHETIC MEDICATION; PROPOFOL;

EID: 8744275147     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0807-3     Document Type: Article

References (27)

1. Bryson HM, Fulton BR, Faulds D (1995) Propofol An update of its use in anaesthesia and conscious sedation. Drugs 50:513-559
2. Baker MT, Chadam MV, Ronnenberg WC Jr (1993) Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesth Analg 76:817-821
3. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC (1995) Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth 74:558-562
4. Janicki PK, James MF, Erskine WA (1992) Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. Br J Anaesth 68:311-312
5. Leung BP, Miller E, Park GR (1997) The effect of propofol on midazolam metabolism in human liver microsome suspension. Anaesthesia 52:945-948
6. McKillop D, Wild MJ, Butters CJ, Simcock C (1998) Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 28:845-853
7. Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A (1999) Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther 66:110-107
8. Mertens MJ, Vuyk J, Olofsen E, Bovill JG, Burm AG (2001) Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers. Anesthesiology 94:949-957
9. Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447-474
10. Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525-530
11. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281-285
12. Markowitz JS, Wells BG, Carson WH (1995) Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 29:603-609
13. Vanden Bossche H, Koymans L, Moereels H (1995) P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 67:79-100
14. Murray M (1997) Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 24:465-470
15. Tanaka E (1998) Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23:403-416
16. Sebel PS, Lowdon JD (1989) Propofol: a new intravenous anesthetic. Anesthesiology 71:260-277
17. Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M (1988) Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 18:429-440
18. Sneyd JR, Simons PJ, Wright B (1994) Use of proton nmr spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica 24:1021-1028
19. Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P (1998) Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 80:788-795
20. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110-119
21. Stresser DM, Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525
22. Baker MT, Chadam MV, Ronnenberg WC Jr (1993) Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesth Analg 76:817-821
23. Kharasch ED, Thummel KE (1993) Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth Analg 76:1033-1039
24. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED (1995) Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 23:490-496
25. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M (1996) Identification of human liver cytochrome P450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82:167-172
26. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96
27. Leung BP, Miller E, Park GR (1997) The effect of propofol on midazolam metabolism in human liver microsome suspension. Anaesthesia 52:945-948